How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?
As the complexity of therapeutic modalities — from ADCs and bispecifics to cell and gene therapies and RNA-based medicines — continues to accelerate, CDMOs are being pushed beyond generalist models toward deliberate, deep specialization in targeted areas. Differentiation no longer hinges on capacity or broad service menus but on owning the highest-barrier steps, integrating process development, analytics, and regulatory expertise, and delivering seamless execution from discovery through commercial supply.
Explore how leading CDMOs are navigating this shift and building the specialized capabilities that will define the next era of drug development — read the full roundtable article here.
As the complexity of therapeutic modalities — from ADCs and bispecifics to cell and gene therapies and RNA-based medicines — continues to accelerate, CDMOs are being pushed beyond generalist models toward deliberate, deep specialization in targeted areas. Differentiation no longer hinges on capacity or broad service menus but on owning the highest-barrier steps, integrating process development, analytics, and regulatory expertise, and delivering seamless execution from discovery through commercial supply.
Explore how leading CDMOs are navigating this shift and building the specialized capabilities that will define the next era of drug development — read the full roundtable article here.
Share article
Related Content